Genitourinary Syndrome of Menopause Induced by Breast Cancer Treatments: A Randomized Clinical Trial Comparing Multimodal Pelvic Floor Physiotherapy and Fractional CO2 Laser Therapy

What this Trial Is About

Researchers are evaluating two non-hormonal treatments to reduce symptoms of genitourinary syndrome of menopause (GSM) in women who have survived breast cancer. GSM is common in this group due to hormonal changes caused by cancer treatments, and effective non-hormonal options are needed. The trial compares multimodal pelvic floor physiotherapy (PPT) and fractional CO2 vaginal laser therapy to see which better improves pelvic pain, sexual function, and quality of life. Participants will be randomly assigned to one of two groups. One group will receive three monthly sessions of fractional CO2 vaginal laser therapy, each lasting about 15 minutes without anesthesia. The other group will attend eight personalized sessions of multimodal PPT over several weeks, including pelvic floor muscle training, non-ablative radiofrequency therapy, pelvic health education, and use of vaginal moisturizers. Women will be evaluated at the start, immediately after treatments, and at 3, 6, and 12 months post-intervention. Assessments include sexual function, pelvic pain levels, vaginal health, pelvic floor muscle function, and quality of life. The study will also monitor any adverse effects and analyze the cost-effectiveness of each treatment. This participation timeline allows researchers to understand both short- and longer-term effects of the therapies.

Genitourinary Syndrome of Menopause in Breast Cancer